City of Hope

City of Hope, a NCI-designated Comprehensive Cancer Center

Page Title

Skip Navigation

Global Navigation



Border Border 		  
  PROFILE 
The following is a list of available studies directed by  Margaret O'Donnell, MD  
Search results:  2  Clinical trial(s) found  (Page 1 of 1 )
Results per page: 25 50 100 All 1-2 Trials Jump to page:

COH Protocol Number: 12110 ClinicalTrials.gov Number: NCT01522976

Principal Investigator: Margaret O'Donnell, MD
Sponsor: Cooperative Group

Title:  SWOG S1117: A Randomized Phase II Study of Azacitidine in Combination with Lenalidomide (NSC-703813) vs. Azacitidine Alone vs. Azacitidine in Combination with Vorinostat (NSC-701852) for Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)

COH Protocol Number: 10140 ClinicalTrials.gov Number: NCT00792948

Principal Investigator: Margaret O'Donnell, MD
Sponsor: Cooperative Group

Title:  SWOG S0805: Phase II Study of Combination of Hyper-CVAD and Dasatinib (NSC-732517) with or without Allogeneic Stem Cell Transplant in Patients with Philadelphia (Ph) Chromosome Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL) (A BMT Study)

 
Results per page: 25 50 100 All 1-2 Trials Jump to page:

 
 
  
© 2009 City of Hope.
1500 East Duarte Road
Duarte, California 91010
626-256-HOPE (4673)
NCI CCC LogoCity of Hope, An NCI-designated Comprehensive Cancer Center, is an innovative biomedical research, treatment and educational institution dedicated to the prevention and cure of cancer and other life-threatening illness.
Best Of logoCity of Hope has been named one of "America's Best Hospitals" in cancer and urology by U.S. News & World Report. Read more here...
NCI CCC LogoThe National Comprehensive Cancer Network (NCCN), a not-for-profit alliance of 21 of the world’s leading cancer centers, is dedicated to improving the quality and effectiveness of care provided to patients with cancer.
Best Of logoWe subscribe to the HONcode of the Healthcare on the Net Foundation.